{"transactions":[{"id":918396,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock option (right to buy)","published_at":"2026-02-05T21:45:03.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":1800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":1800000,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":1800000},"source":{"system":"sec-edgar","filing":"0001193125-26-039537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526039537/ownership.xml","form_type":"4"}},{"id":1054159,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-28T21:00:09.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share (\"Common Stock\"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the \"Plan\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":600000,"derivative":{"exercise_price":2.17,"expiration_date":"2035-08-26","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000950170-25-112045","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025112045/ownership.xml","form_type":"4"}},{"id":1623696,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-23T21:50:07.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":140000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000950170-24-019434","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024019434/ownership.xml","form_type":"4"}},{"id":1951146,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-16T20:28:08.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":275000,"derivative":{"exercise_price":0.54,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001437749-23-006909","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923006909/rdgdoc.xml","form_type":"4"}},{"id":2158876,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-09-15T20:45:17.000Z","date":"2022-09-13","kind":"grant","acquired":true,"shares":274875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":274875,"derivative":{"exercise_price":0.71,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":274875},"source":{"system":"sec-edgar","filing":"0001209191-22-050082","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000120919122050082/doc4.xml","form_type":"4"}},{"id":2325542,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-19T01:15:23.000Z","date":"2022-03-16","kind":"grant","acquired":true,"shares":24972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors."}],"balance_after":24972,"derivative":{"exercise_price":1.78,"expiration_date":"2032-03-16","underlying":"Common Stock","underlying_shares":24972},"source":{"system":"sec-edgar","filing":"0000899243-22-011660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000089924322011660/doc4.xml","form_type":"4"}},{"id":2496619,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Earnout Rights (Restricted Stock Units)","published_at":"2021-11-25T00:37:14.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":108086,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."}],"balance_after":108086,"derivative":{"underlying":"Common Stock","underlying_shares":108086},"source":{"system":"sec-edgar","filing":"0001493152-21-029889","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221029889/ownership.xml","form_type":"4/A","original_submission_date":"2021-10-26"}},{"id":2496618,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-25T00:37:14.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":81425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":81425,"derivative":{"exercise_price":0.5,"expiration_date":"2027-03-12","underlying":"Common Stock","underlying_shares":81425},"source":{"system":"sec-edgar","filing":"0001493152-21-029889","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221029889/ownership.xml","form_type":"4/A","original_submission_date":"2021-10-26"}},{"id":2496617,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-25T00:37:14.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":104689,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":104689,"derivative":{"exercise_price":0.5,"expiration_date":"2027-03-12","underlying":"Common Stock","underlying_shares":104689},"source":{"system":"sec-edgar","filing":"0001493152-21-029889","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221029889/ownership.xml","form_type":"4/A","original_submission_date":"2021-10-26"}},{"id":2535067,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Earnout Rights (Restricted Stock Units)","published_at":"2021-10-27T01:48:38.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":108086,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the Earnout Shares will be released if within the five-year period after the closing (the \"Earnout Period\"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the \"Earnout Shares\"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]"}],"balance_after":108086,"derivative":{"underlying":"Common Stock","underlying_shares":108086},"source":{"system":"sec-edgar","filing":"0001493152-21-026384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026384/ownership.xml","form_type":"4"}},{"id":2535066,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-10-27T01:48:38.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":11632,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":11632,"derivative":{"exercise_price":1.25,"expiration_date":"2030-04-27","underlying":"Common Stock","underlying_shares":11632},"source":{"system":"sec-edgar","filing":"0001493152-21-026384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026384/ownership.xml","form_type":"4"}},{"id":2535065,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-10-27T01:48:38.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":69793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":69793,"derivative":{"exercise_price":0.5,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":69793},"source":{"system":"sec-edgar","filing":"0001493152-21-026384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026384/ownership.xml","form_type":"4"}},{"id":2535064,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-10-27T01:48:38.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":81425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":81425,"derivative":{"exercise_price":0.5,"expiration_date":"2027-03-27","underlying":"Common Stock","underlying_shares":81425},"source":{"system":"sec-edgar","filing":"0001493152-21-026384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026384/ownership.xml","form_type":"4"}},{"id":2535063,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-10-27T01:48:38.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":104689,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the \"Business Combination Agreement\"), by and among Big Cypress Acquisition Corp. (\"BCYP\"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Old SAB Biotherapeutics\"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to \"SAB Biotherapeutics, Inc.\" (\"New SAB Biotherapeutics\" or \"Issuer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":104689,"derivative":{"exercise_price":0.5,"expiration_date":"2027-03-27","underlying":"Common Stock","underlying_shares":104689},"source":{"system":"sec-edgar","filing":"0001493152-21-026384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026384/ownership.xml","form_type":"4"}}]}